CARsgen Life Sciences

CARsgen Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative CAR-T cell therapies for the treatment of hematologic malignancies and solid tumors. The company has established a comprehensive pipeline targeting various antigens, including Glypican 3, Claudin 18.2, and B-cell maturation antigen. CARsgen operates integrated platforms for target discovery, antibody development, and clinical-grade virus and cell manufacturing. With operations in China and the United States, the company aims to address unmet medical needs in oncology through its proprietary technology platforms like CycloCAR and THANK-uCAR. Their lead product, zevorcabtagene autoleucel, has received approval in China for relapsed or refractory multiple myeloma. The company is also advancing CT041, a first-in-class CAR-T candidate targeting Claudin 18.2, which is in pivotal trials for gastric cancer.